Johnson & Johnson unit enters $310 million antibiotic deal

Share this article:
Basilea Pharmaceutica of Switzerland has entered into an exclusive worldwide agreement with Johnson & Johnson subsidiary Cilag International for the new antibiotic ceftobiprole.
Cilag will pay a "substantial" upfront payment in the deal worth up to $310 million in scheduled payments.
Ceftobiprole is currently in phase III clinical trials in complicated skin and skin structure infections and hospital-acquired pneumonia trials are in preparation. Both indications have been granted fast track designation by the FDA.
Ortho-McNeil, another Johnson & Johnson company, will market ceftobiprole in the U.S. and its affiliate companies, known as Janssen-Cilag, will market the product outside the U.S.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions